CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bifrost Biosystems, a pioneer in Optical Pooled Screening (OPS) technologies, today announced the appointment of experienced life sciences industry executive, Jonas Jarvius, PhD, as Chief Executive Officer, President and Director. He brings to Bifrost over 15 years of C-level executive experience from both private and public companies translating innovative technologies into commercial products that impact human health outcomes..

马萨诸塞州剑桥市——（商业新闻短讯）——光学联合筛选（OPS）技术的先驱Bifrost Biosystems今天宣布任命经验丰富的生命科学行业高管Jonas Jarvius博士为首席执行官、总裁兼董事。他为Bifrost带来了超过15年的私营和上市公司C级管理经验，将创新技术转化为影响人类健康结果的商业产品。。

“On behalf of our board of directors, we enthusiastically welcome Jonas to his new role as President and CEO of Bifrost and look forward to the many successes ahead for him and the team,” said Shawn Marcell, co-founder and Chairman of Bifrost. “Jonas’s strong technical background combined with his demonstrated business acumen will bring a level of rigor and visionary leadership essential to driving Bifrost’s success.”.

Bifrost联合创始人兼董事长肖恩·马塞尔（ShawnMarcell）表示：“我们代表董事会热烈欢迎乔纳斯（Jonas）担任Bifrost总裁兼首席执行官，并期待他和团队取得更多成功。”。“乔纳斯强大的技术背景加上他表现出的商业敏锐，将带来对推动比弗罗斯特成功至关重要的严谨和富有远见的领导力。”。

Dr. Jarvius earned his doctoral degree in Molecular Medicine from Uppsala University where his research focused on developing Proximity Ligation and Padlock probe-based molecular recognition technologies as well as isothermal amplification techniques. Several of these technologies have subsequently been commercialized in successful companies such as Olink, Q-linea, Umbrella Science, and Sigolis (Ginolis) where Jonas is a founder or cofounder.

Jarvius博士在乌普萨拉大学获得了分子医学博士学位，他的研究重点是开发基于邻近连接和挂锁探针的分子识别技术以及等温扩增技术。其中一些技术随后在成功的公司中商业化，例如Olink，Q-linea，Umbrary Science和Sigolis（Ginolis），Jonas是这些公司的创始人或联合创始人。

Dr. Jarvius most recently served as chief executive officer of Q-Linea, a diagnostics company focused on improving sepsis treatment and reducing antimicrobial resistance. In this role, he led the company from an initial technology to a multinational commercial enterprise..

Jarvius博士最近担任Q-Linea的首席执行官，Q-Linea是一家专注于改善败血症治疗和降低抗菌素耐药性的诊断公司。在这个职位上，他带领公司从最初的技术发展为跨国商业企业。。

“I am excited to lead Bifrost and work with such an exceptionally talented team,” said Jonas. “In my career, I have had the good fortune of developing and commercializing disruptive technologies in protein interaction analysis, rapid Antibiotic Susceptibility Testing and advanced microfluidics. The Bifrost OPS technology is similarly well-positioned to disrupt drug discovery and empower researchers to make better-informed decisions.”.

乔纳斯说：“我很高兴能领导比弗罗斯特，并与如此才华横溢的团队合作。”。“在我的职业生涯中，我有幸在蛋白质相互作用分析，快速抗生素敏感性测试和先进微流体技术中开发和商业化破坏性技术。Bifrost OPS技术同样能够破坏药物发现，并使研究人员能够做出更明智的决定。”。

Bifrost's advanced OPS platform revolutionizes functional genomics through high-speed, microscopy-based pooled single-cell screens of CRISPR-based perturbations. The resulting extensive dataset facilitates understanding of complex biological processes, target identification and validation – actionable insights that accelerate discovery pipelines in biological research..

Bifrost的高级OPS平台通过基于CRISPR的扰动的高速，基于显微镜的汇总单细胞筛选，彻底改变了功能基因组学。由此产生的广泛数据集有助于理解复杂的生物过程，目标识别和验证-可操作的见解，加速生物研究中的发现流程。。

About Bifrost Biosystems

关于Bifrost Biosystems

Bifrost is a life sciences tools company offering high-throughput single-cell optical pooled screening and analysis solutions that deliver insights into functional cell biology and drug discovery. The lead OPS platform is well-aligned with the trending needs of drug discovery research for speed, scale, and quality understanding of biology within budget.

Bifrost是一家生命科学工具公司，提供高通量单细胞光学池筛选和分析解决方案，为功能细胞生物学和药物发现提供见解。lead OPS平台与药物发现研究在预算内对生物学的速度，规模和质量理解的趋势需求非常吻合。

Learn more at www.bifrost.bio..

请访问www.bifrost.bio了解更多信息。。